On October 16, 2014, the fee-for-service (FFS) pharmacy program implemented clinical criteria for Hepatitis C Virus (HCV) drug therapy, as was recommended by the Drug Utilization Review Board (DURB) at the September 18, 2014 meeting. Included in this criteria were the following ...
This interactive workshop, led by renowned hepatologist Dr. Robert Gish, is designed to provide health care providers and their medical team with core medical knowledge of hepatitis B (HBV) and hepatitis C (HCV).
- Sign On | Urge Congress to Appropriate Opioid Funding for Hep C/ HIV February 14, 2018
- Training Manual for Treatment Activists | Hep C & HIV Coinfection February 2, 2018
- Letter to Administration: “America Falls Behind in Hepatitis Elimination Efforts” January 9, 2018
- NY City Council Discretionary Funding Application (Due 2/20/18) December 22, 2017
February 23 @ 8:00 am - 10:00 am EST
February 26 @ 9:00 am - 5:00 pm EST
March 2 @ 8:00 am - 10:00 am EST